AstraZeneca Gets CDSCO Panel Nod for Enhertu 100mg for additional indication of breast cancer
New Delhi: Noting an unmet medical need in the country, the Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organisation (CDSCO) has approved AstraZeneca’s Trastuzumab deruxtecan concentrate solution for infusion 100mg (Enhertu 100mg) for the treatment of adult patients with unresectable or metastatic HER2-Low (IHC 1+ or IHC 2+/ISH-) breast cancer who […]